56O A randomized, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in resectable stage IIIA and IIIB (T3N2) non-small-cell lung cancer

Subjects

Subjects :

Oncology
Immunology and Allergy

Details

ISSN :

25900188

Volume :

16

Database :

OpenAIRE

Journal :

Immuno-Oncology and Technology

Accession number :

edsair.doi...........767e81c7b8e8e24f13215f4247f6de49

Full Text :

https://doi.org/10.1016/j.iotech.2022.100161